When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Jason J. Luke, MD, FACP, an associate professor of medicine in the Division of Hematology/Oncology and director of the Cancer Immunotherapeutics Center within the Immunology and Immunotherapy Program at…
A study composed of patients from across the USA and Europe observed improved outcomes in those treated with both ilixadencel and sunitinib compared with sunitinib alone. here.
In this interview, Shirish M. Gadgeel, MD, MBBS, medical oncologist at Michigan Medicine, University of Michigan, provides insights into multikinase tyrosine kinase inhibitor (TKI) treatments and their varied…
A study completed by researchers in China, of patients with renal cell carcinoma (RCC), attempted to both validate previous conclusions and look at the influencing factors of perioperative renal…
In this interview, David Polsky, MD, PhD, shares details about his advanced laboratory tumor detection technology and the study results presented at ASCO 2020. Dr. Polsky suggests that…
Rogerio C. Lilenbaum, MD, director of the Banner MD Anderson Cancer Center, discusses the ways physicians practicing in different care institutions order molecular panels for patients with nonsquamous…
In this “Practice Pearls” webinar hosted by Pharmacy Times, expert panelists discuss important topics regarding the treatment of patients with acute myeloid leukemia (AML). Panelists: Katie Culos, PharmD,…
Rajneesh Nath, MD, medical oncologist at the Banner MD Anderson Cancer Center, discusses early results from the phase 3 SIERRA trial investigating the efficacy of Iomab-B and protocol-specified…
Anna C. Pavlick, DO, director of High Reliability Organization Initiatives and co-director of the Melanoma Program at NYU Langone Health’s Perlmutter Cancer Center, overviews next generation MEK and…
Ragini Kudchadkar, MD, associate professor in the Department of Hematology and Medical Oncology, and associate director of the Hematology and Medical Oncology Fellowship Program – Clinical/Service at Emory…
